November 12, 2020 -- Proteintech and HebeCell have announced a partnership to develop nanobody-based chimeric antigen receptors (nCARs) for cancer cellular immunotherapy use.
The nCAR technology will be used to develop induced pluripotent stem cells (iPSCs) -derived natural killer cells, according to the firms. Proteintech recently acquired ChromoTek, which augmented its nanobody development resources, while HebeCell holds intellectual property regarding natural killer cells.